Who are Probiotics Lactobacillus Rhamnosus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Probiotic (Lactobacillus reuteri Prodentis, Gynomunal® gel, Trimo-San vaginal gel, Probiotics (Lacidofil®), "Probiotics" and "Metronidazole", Combizym + Bifidobacteri.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/probiotics-lactobacillus-rhamnosus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Probiotics Lactobacillus Rhamnosus — Competitive Intelligence Brief

Probiotics Lactobacillus Rhamnosus (Probiotics Lactobacillus Rhamnosus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastrointestinal.

phase 3 Probiotic Gastrointestinal Small molecule Live · refreshed every 30 min

Target snapshot

Probiotics Lactobacillus Rhamnosus (Probiotics Lactobacillus Rhamnosus) — Aga Khan University. Probiotics Lactobacillus Rhamnosus modulates the gut microbiome to improve immune function and overall health.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Probiotics Lactobacillus Rhamnosus TARGET	Probiotics Lactobacillus Rhamnosus	Aga Khan University	phase 3	Probiotic
Probiotic (Lactobacillus reuteri Prodentis	Probiotic (Lactobacillus reuteri Prodentis	Universidad de Colima	marketed	Probiotic
Gynomunal® gel	Gynomunal® gel	Derming SRL	marketed	Vaginal probiotic/microbiota restorer
Trimo-San vaginal gel	Trimo-San vaginal gel	The University of Texas Health Science Center, Houston	marketed	Vaginal pH regulator / Probiotic adjunct
Probiotics (Lacidofil®)	Probiotics (Lacidofil®)	Chuncheon Sacred Heart Hospital	marketed	Probiotic
"Probiotics" and "Metronidazole"	"Probiotics" and "Metronidazole"	Peking University Shenzhen Hospital	marketed	Antibiotic + Probiotic combination
Combizym + Bifidobacteri	Combizym + Bifidobacteri	RenJi Hospital	marketed	Enzyme and probiotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Probiotics Lactobacillus Rhamnosus — Competitive Intelligence Brief. https://druglandscape.com/ci/probiotics-lactobacillus-rhamnosus. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab